Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 6Terminated 3Recruiting 3Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 20Myeloid 14Lymphoid 14CNS 4Sarcoma 3Plasma cell 3Classical hematology 3Gynecologic 2Breast 2Genitourinary 1Dermatologic 1

Conditions

Lymphoma 2Leukemia 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunologic Deficiency Syndromes 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1Anemia 1

Interventions

Cyclophosphamide 17fludarabine phosphate 14Whole-Body Irradiation 11Mycophenolic Acid 9Epoetin Alfa 9Cyclosporine 9Busulfan 9fludarabine 8Cord Blood Stem Cell Transplantation 8Antilymphocyte Serum 8Filgrastim 6Tacrolimus 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Methotrexate 5Darbepoetin alfa 5Dalteparin 5Cytarabine 5eltrombopag 4Tinzaparin 4Thiotepa 4Platelet Transfusion 4Melphalan 4Etoposide 4Arsenic Trioxide 4thymoglobulin 3epoetin beta 3Vorinostat 3Transplantation 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × thymoglobulin × Classical hematology × Clear all
NCT00801931 2019-03-27

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Columbia University

Phase 1/2 Terminated
1 enrolled 8 charts
CNSClassical hematologyLymphoidOther hematologic neoplasm

Anemia, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Neuroblastoma

NCT00593554 2018-04-10

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Indiana University

Phase 2 Terminated
9 enrolled 13 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00720629 2014-07-18

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
8 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡